Platinum-induced hearing loss after treatment for childhood cancer

Medicine and Dentistry

• Childhood Cancer 100%
• Hearing Impairment 100%
• Platinum 100%
• Prevalence 45%
• Platinum Derivative 30%
• Cisplatin 25%
• Ototoxicity 25%
• Carboplatin 15%
• Malignant Neoplasm 10%
• Cancer Therapy 10%
• Tinnitus 10%
• Odds Ratio 10%
• Oncology 5%
• Adverse Event 5%
• Anthracycline 5%
• Complication of Treatment 5%
• Systematic Review 5%
• Randomized Controlled Trial 5%
• Cancer Treatment 5%
• Disease Marker 5%
• Pediatric Hematology 5%
• Controlled Clinical Trial 5%
• Oxaliplatin 5%
• Aminoglycoside Antibiotic Agent 5%
• Noise Pollution 5%
• Hearing Test 5%
• Adolescence 5%
• Diagnostic Test 5%
• Cohort Studies 5%
• Diagnostic Testing 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Childhood Cancer 100%
• Hearing Impairment 100%
• Platinum 100%
• Prevalence 45%
• Platinum Derivative 30%
• Cisplatin 25%
• Ototoxicity 25%
• Carboplatin 15%
• Malignant Neoplasm 10%
• Tinnitus 10%
• Anthracycline 5%
• Randomized Controlled Trial 5%
• Oxaliplatin 5%
• Cohort Study 5%
• Disease Marker 5%
• Adverse Event 5%
• Controlled Clinical Trial 5%
• Aminoglycoside Antibiotic Agent 5%

Keyphrases

• Hearing Loss Prevalence 25%
• Nonconsecutive 6%
• Excess Noise 6%
• Non-anthracycline 6%